CN114423751B - 用作选择性aurora a抑制剂的新型杂环化合物 - Google Patents

用作选择性aurora a抑制剂的新型杂环化合物 Download PDF

Info

Publication number
CN114423751B
CN114423751B CN202180003823.8A CN202180003823A CN114423751B CN 114423751 B CN114423751 B CN 114423751B CN 202180003823 A CN202180003823 A CN 202180003823A CN 114423751 B CN114423751 B CN 114423751B
Authority
CN
China
Prior art keywords
methyl
alkyl
group
membered
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180003823.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN114423751A (zh
Inventor
成岱
陈明明
李阿敏
李海军
杨贵群
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jacobio Pharmaceuticals Co Ltd
Original Assignee
Jacobio Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jacobio Pharmaceuticals Co Ltd filed Critical Jacobio Pharmaceuticals Co Ltd
Priority to CN202310353468.8A priority Critical patent/CN116354936A/zh
Publication of CN114423751A publication Critical patent/CN114423751A/zh
Application granted granted Critical
Publication of CN114423751B publication Critical patent/CN114423751B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN202180003823.8A 2020-01-22 2021-01-22 用作选择性aurora a抑制剂的新型杂环化合物 Active CN114423751B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310353468.8A CN116354936A (zh) 2020-01-22 2021-01-22 用作选择性aurora a抑制剂的新型杂环化合物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/073786 2020-01-22
CN2020073786 2020-01-22
CNPCT/CN2020/076159 2020-02-21
CN2020076159 2020-02-21
CNPCT/CN2020/085922 2020-04-21
CN2020085922 2020-04-21
PCT/CN2021/073169 WO2021147974A1 (en) 2020-01-22 2021-01-22 Novel heterocyclic compounds useful as aurora a selective inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310353468.8A Division CN116354936A (zh) 2020-01-22 2021-01-22 用作选择性aurora a抑制剂的新型杂环化合物

Publications (2)

Publication Number Publication Date
CN114423751A CN114423751A (zh) 2022-04-29
CN114423751B true CN114423751B (zh) 2023-04-21

Family

ID=76993163

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180003823.8A Active CN114423751B (zh) 2020-01-22 2021-01-22 用作选择性aurora a抑制剂的新型杂环化合物
CN202310353468.8A Pending CN116354936A (zh) 2020-01-22 2021-01-22 用作选择性aurora a抑制剂的新型杂环化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310353468.8A Pending CN116354936A (zh) 2020-01-22 2021-01-22 用作选择性aurora a抑制剂的新型杂环化合物

Country Status (13)

Country Link
US (2) US20230128198A1 (https=)
EP (1) EP4093736A4 (https=)
JP (1) JP7688646B2 (https=)
KR (1) KR102828343B1 (https=)
CN (2) CN114423751B (https=)
AU (1) AU2021209744B2 (https=)
CL (1) CL2022001951A1 (https=)
CO (1) CO2022010878A2 (https=)
IL (1) IL294247B2 (https=)
MX (1) MX2022009059A (https=)
PH (1) PH12022551858A1 (https=)
TW (1) TWI785474B (https=)
WO (1) WO2021147974A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3823974A1 (en) 2018-07-20 2021-05-26 F. Hoffmann-La Roche AG Sulfonimidamide compounds as inhibitors of interleukin-1 activity
CN112239465A (zh) 2019-07-16 2021-01-19 微境生物医药科技(上海)有限公司 极光激酶抑制剂及其用途
CN112898292A (zh) 2019-12-03 2021-06-04 微境生物医药科技(上海)有限公司 新型极光激酶抑制剂及其用途
JP2025506772A (ja) * 2022-02-23 2025-03-13 リペア セラピューティクス インコーポレイテッド ポロ様キナーゼ４（ｐｌｋ４）阻害剤、医薬組成物、ならびにそれらを調製する方法、及びそれらの使用方法
CN115057811B (zh) * 2022-05-26 2024-06-14 安庆朗坤药业有限公司 一种2-溴甲基-3,5-二氟吡啶的制备方法
CN115322143B (zh) * 2022-07-21 2023-07-14 安徽德诺医药股份有限公司 一种4-哌啶甲酸叔丁酯盐酸盐的制备方法
WO2024230647A1 (zh) * 2023-05-05 2024-11-14 苏州信诺维医药科技股份有限公司 杂环类化合物、其药物组合物和其应用
CN116903587B (zh) * 2023-06-01 2024-03-22 三峡大学 一种角鲨烯环氧酶抑制剂及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008026768A1 (en) * 2006-08-31 2008-03-06 Banyu Pharmaceutical Co., Ltd Novel aminopyridine derivatives having aurora a selective inhibitory action
WO2009104802A1 (en) * 2008-02-22 2009-08-27 Banyu Pharmaceutical Co., Ltd. Novel aminopyridine derivatives having aurora a selective inhibitory action
CN104159893A (zh) * 2012-02-29 2014-11-19 大鹏药品工业株式会社 新型哌啶化合物或其盐
CN107108567A (zh) * 2014-11-14 2017-08-29 伊莱利利公司 极光激酶a抑制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021006011A (es) * 2018-11-30 2021-09-21 Lilly Co Eli Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
CN112239465A (zh) * 2019-07-16 2021-01-19 微境生物医药科技(上海)有限公司 极光激酶抑制剂及其用途
CN112898292A (zh) * 2019-12-03 2021-06-04 微境生物医药科技(上海)有限公司 新型极光激酶抑制剂及其用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008026768A1 (en) * 2006-08-31 2008-03-06 Banyu Pharmaceutical Co., Ltd Novel aminopyridine derivatives having aurora a selective inhibitory action
CN101528731A (zh) * 2006-08-31 2009-09-09 万有制药株式会社 具有AuroraA选择性抑制作用的新型氨基吡啶衍生物
WO2009104802A1 (en) * 2008-02-22 2009-08-27 Banyu Pharmaceutical Co., Ltd. Novel aminopyridine derivatives having aurora a selective inhibitory action
CN104159893A (zh) * 2012-02-29 2014-11-19 大鹏药品工业株式会社 新型哌啶化合物或其盐
CN107108567A (zh) * 2014-11-14 2017-08-29 伊莱利利公司 极光激酶a抑制剂

Also Published As

Publication number Publication date
CN114423751A (zh) 2022-04-29
JP2023513419A (ja) 2023-03-31
CO2022010878A2 (es) 2022-08-19
CA3161268A1 (en) 2021-07-29
CN116354936A (zh) 2023-06-30
IL294247A (en) 2022-08-01
US11384066B1 (en) 2022-07-12
KR20220131514A (ko) 2022-09-28
MX2022009059A (es) 2022-08-15
JP7688646B2 (ja) 2025-06-04
TW202140449A (zh) 2021-11-01
CL2022001951A1 (es) 2023-04-14
EP4093736A4 (en) 2024-01-10
WO2021147974A1 (en) 2021-07-29
IL294247B1 (en) 2025-07-01
IL294247B2 (en) 2025-11-01
US20230128198A1 (en) 2023-04-27
AU2021209744B2 (en) 2023-08-31
TWI785474B (zh) 2022-12-01
AU2021209744A1 (en) 2022-07-07
EP4093736A1 (en) 2022-11-30
PH12022551858A1 (en) 2024-01-03
KR102828343B1 (ko) 2025-07-04

Similar Documents

Publication Publication Date Title
CN114423751B (zh) 用作选择性aurora a抑制剂的新型杂环化合物
CN114269735B (zh) 二氢或四氢喹唑啉类化合物及其中间体、制备方法和应用
JP7644517B2 (ja) Ｋｒａｓ突然変異型タンパク質阻害剤
EP3880676B1 (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
EP3952870B1 (en) Phosphatidylinositol 3-kinase inhibitors
CA3216163A1 (en) Carboxy-benzimidazole glp-1r modulating compounds
JP7105781B2 (ja) ベンズイミダゾール誘導体、調製方法およびそれらの使用
EP3865488A1 (en) Macrocyclic compound as cdk inhibitor, preparation method therefor, and use thereof in medicine
EP3209651B1 (en) Carbazole derivatives
WO2015077193A1 (en) Inhibitors of lysine methyl transferase
EP2935271A1 (en) Novel substituted imidazoles as casein kinase 1 / inhibitors
KR20200090636A (ko) 피롤로피리미딘 유도체 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
EP4105207A1 (en) Quinolyl phosphine oxide compound, and composition and application thereof
CN115109061B (zh) 三环化合物
CN116848117B (zh) 作为Wee-1抑制剂的稠环化合物
HK40066473B (en) Novel heterocyclic compounds useful as aurora a selective inhibitors
CA3161268C (en) Heterocyclic compounds useful as aurora a selective inhibitors
HK40066473A (zh) 用作选择性aurora a抑制剂的新型杂环化合物
HK40053093A (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
HK40039964A (en) Tricyclic compounds
HK1238642A1 (en) Carbazole derivatives
HK1238642B (en) Carbazole derivatives
HK1187606A1 (zh) 取代的6，6-稠合含氮杂环化合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40066473

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant